A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
Background: Osteosarcoma is the most common primary malignant tumour in young adults. An effective treatment strategy for relapsed patients is still not defined. Pemetrexed is a multitargeted antifolate with a mode of action similar to, and a range of action broader than that of methotrexate. The pr...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12 January 2012
|
| In: |
European journal of cancer
Year: 2012, Volume: 48, Issue: 4, Pages: 564-570 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2011.12.015 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/j.ejca.2011.12.015 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804911010409 
|
| Author Notes: | Florence Duffaud, Gerlinde Egerer, Stefano Ferrari, Hisham Rassam, Ulrike Boecker, B. Bui-Nguyen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1585666165 | ||
| 003 | DE-627 | ||
| 005 | 20230427161349.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 181218s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2011.12.015 |2 doi | |
| 035 | |a (DE-627)1585666165 | ||
| 035 | |a (DE-576)515666165 | ||
| 035 | |a (DE-599)BSZ515666165 | ||
| 035 | |a (OCoLC)1341031066 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Duffaud, Florence |e VerfasserIn |0 (DE-588)1173752056 |0 (DE-627)104360085X |0 (DE-576)515665568 |4 aut | |
| 245 | 1 | 2 | |a A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma |c Florence Duffaud, Gerlinde Egerer, Stefano Ferrari, Hisham Rassam, Ulrike Boecker, B. Bui-Nguyen |
| 264 | 1 | |c 12 January 2012 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.12.2018 | ||
| 520 | |a Background: Osteosarcoma is the most common primary malignant tumour in young adults. An effective treatment strategy for relapsed patients is still not defined. Pemetrexed is a multitargeted antifolate with a mode of action similar to, and a range of action broader than that of methotrexate. The primary objective of this phase II study was to determine tumour response rate in patients with high-grade, advanced/metastatic osteosarcoma. Secondary end-points included progression-free survival (PFS), overall survival (OS) and safety. Methods: Pemetrexed 500mg/m2 was administered on day 1 of 21-day cycles with folic acid and vitamin B12 supplementation. At least 5 tumour responses in a targeted population of 32 were required to consider further investigation. Results: Thirty-two patients (median age, 43.3years; range, 18.6-76.0) with 1 prior chemotherapy regimen for high-grade advanced/metastatic osteosarcoma were enrolled. Thirty (93.8%) patients had an ECOG performance status ⩽1 and 29 (90.6%) had metastases in the lung. One patient had partial response (3.1%) and 5 (15.6%) had stable disease. Median PFS and OS were 1.4months (95% CI: 1.4-1.7) and 5.5months (95% CI: 2.3-10.5), respectively. The most common drug-related grade 3/4 toxicities were leukopaenia, asthaenia and elevated alanine aminotransferase in 3 (9.4%) patients each. One patient died due to multi-organ failure considered possibly related to the study drug. Conclusions: Pemetrexed 500mg/m2 administered on day 1 of 21-day cycles as second-line treatment to patients with advanced/metastatic high-grade osteosarcoma was generally well tolerated but did not meet minimal response expectations for further investigation in this patient population. | ||
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Osteosarcoma | |
| 650 | 4 | |a Pemetrexed | |
| 650 | 4 | |a Phase II | |
| 650 | 4 | |a Relapse | |
| 650 | 4 | |a Response | |
| 650 | 4 | |a Second-line | |
| 700 | 1 | |a Egerer, Gerlinde |e VerfasserIn |0 (DE-588)105502168X |0 (DE-627)792516745 |0 (DE-576)167430882 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 48(2012), 4, Seite 564-570 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma |
| 773 | 1 | 8 | |g volume:48 |g year:2012 |g number:4 |g pages:564-570 |g extent:7 |a A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2011.12.015 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0959804911010409 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20181218 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 105502168X |a Egerer, Gerlinde |m 105502168X:Egerer, Gerlinde |d 910000 |d 910100 |e 910000PE105502168X |e 910100PE105502168X |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 999 | |a KXP-PPN1585666165 |e 3038548235 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Duffaud, Florence","given":"Florence","role":"aut","family":"Duffaud"},{"family":"Egerer","display":"Egerer, Gerlinde","role":"aut","given":"Gerlinde"}],"name":{"displayForm":["Florence Duffaud, Gerlinde Egerer, Stefano Ferrari, Hisham Rassam, Ulrike Boecker, B. Bui-Nguyen"]},"note":["Gesehen am 18.12.2018"],"relHost":[{"id":{"zdb":["1468190-0"],"issn":["1879-0852"],"eki":["266883400"]},"disp":"A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcomaEuropean journal of cancer","note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"corporate":[{"display":"European Organization for Research on Treatment of Cancer","role":"isb"},{"display":"European Association for Cancer Research","role":"isb"},{"role":"isb","display":"European School of Oncology"}],"origin":[{"dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}],"recId":"266883400","titleAlt":[{"title":"EJC online"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"European journal of cancer","title_sort":"European journal of cancer"}],"language":["eng"],"part":{"volume":"48","text":"48(2012), 4, Seite 564-570","year":"2012","pages":"564-570","extent":"7","issue":"4"},"pubHistory":["28.1992 -"]}],"physDesc":[{"extent":"7 S."}],"id":{"eki":["1585666165"],"doi":["10.1016/j.ejca.2011.12.015"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1585666165","origin":[{"dateIssuedDisp":"12 January 2012","dateIssuedKey":"2012"}],"language":["eng"],"title":[{"title":"A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma","title_sort":"phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma"}]} | ||
| SRT | |a DUFFAUDFLOPHASEIITRI1220 | ||